Health care is undergoing an important and well-needed shift from a one-size-fits-all approach to more personalized, precise, patient-focused care. A similar approach needs to be implemented at scale ...
Our proposed Toxicity Adaptive Lists Design (TALE) is straightforward to implement, requiring the prespecification of a small number of parameters that define rules governing dose escalation, ...
Real-world data (RWD) is transforming clinical research, augmenting existing randomized controlled trial (RCT) data to de-risk studies and improve generalizability. With regulators setting clearer ...
Bioequivalence studies are an essential component in the development and approval of generic pharmaceutical products, ensuring that they perform similarly to their reference counterparts. These ...
The International Drug Development Institute (IDDI) is reinforcing its position as a contract research organization by introducing innovative clinical trial design and analysis solutions that are ...
This is the Applied Clinical Trials Brief —your fast track to the latest insights shaping clinical operations and drug development.
Outcome-adaptive randomization is one of the possible elements of an adaptive trial design in which the ratio of patients randomly assigned to the experimental treatment arm versus the control ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results